Clinical trials: Hemostatic Disorders
Multiple Myeloma
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
- Trial name
- NCT01122875
- Testing
- MFGR1877S
- Where
- 12 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Retreatment Study With Bortezomib for Multiple Myeloma
The purpose of this study is to monitor such factors as a past history, a previous history of drug use, the degree of response to initial treatment, the frequency of previous therapies, age, Eastern Cooperative Oncology Group…
- Trial name
- NCT01030302
- Testing
- bortezomib
- Volunteers
- 56 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma
CP-751,871 Treatment For Patients With Multiple Myeloma
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
- Trial name
- NCT01536145
- Testing
- CP-751,871
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
B-Cell Lymphoma, B-Cell Leukemia
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
- Trial name
- PCYC-04753 (NCT00849654)
- Testing
- PCI-32765
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pharmacyclics LLC.
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Multiple Myeloma
the Safety and Efficacy of SENL103 Autologous T Cell Injection
To observe the safety and efficacy of SENL103 cells in the treatment of patients with recurrent or refractory plasma cell blood tumors.
- Trial name
- NCT06067581
- Testing
- SENL103
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of…
- Trial name
- NCT00934154
- Testing
- Thalidomide, Melphalan+Prednisolone
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Cigdem Sahinbas YILMAZ
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
Multiple Myeloma
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation…
- Trial name
- NCT03828292
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
- Trial name
- NCT02157636
- Testing
- CPI-0610
- Volunteers
- 30 people
- Sponsor
- Constellation Pharmaceuticals
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00530816
- Testing
- carfilzomib
- Where
- 30 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Multiple Myeloma
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Primary objective: To assess the safety of ITF 2357 administered once weekly at high pulse dose in patients with relapsing/refractory multiple myeloma. Secondary objectives: 1.
- Trial name
- NCT00792506
- Testing
- ITF2357
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Italfarmaco
Multiple Myeloma
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
- Trial name
- NCT00925782
- Testing
- Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection, Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Multiple Myeloma
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously…
- Trial name
- NCT00111319
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hereditary Hemorrhagic Telangiectasia
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with…
- Trial name
- NCT07743671
- Testing
- Engasertib
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vaderis Therapeutics AG
Multiple Myeloma
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
Teclistamab pre-approval access in relapsed or refractory multiple myeloma.
- Trial name
- NCT05161598
- Testing
- Teclistamab
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study of ENMD-2076 in Patients With Multiple Myeloma
Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00806065
- Testing
- ENMD-2076
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- CASI pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.